Event driven update on Tango Therapeutics

Tango Therapeutics (TNGX) has been in focus after appointing Malte Peters as CEO, shifting former CEO Barbara Weber to Executive Chair, signing a supply agreement with ERAS for pan RAS, and outlining upcoming pivotal trials.

The stock has been volatile around these company updates, with a 1-day share price return of 8.25% and a 90-day share price return of 80.96%, while the 1-year total shareholder return is extremely large.

If you are looking beyond a single biotech, this is a good moment to see what else is moving across 33 healthcare AI stocks.

With Tango up 81% over 90 days and trading only about 5% below one analyst price target of US$23.90, the key question now is whether recent progress is fully reflected in the share price or if the stock still offers a buying opportunity that the market has not yet priced in.

Preferred Price to Book Multiple of 9.5x: Is it justified?

Tango Therapeutics currently trades on a P/B of 9.5x, compared with an industry average of 2.3x and a peer average of 3.6x, so the stock is priced well above typical biotech benchmarks at the last close of $22.71.

The P/B ratio compares the company’s market value to its book value, which is essentially net assets on the balance sheet. For a biotech that is still loss making, investors often lean on P/B because traditional earnings based metrics such as P/E are not meaningful when there is a net loss.

Here, the market is assigning a materially higher P/B multiple than both the broader US biotech group at 2.3x and closer peers at 3.6x. This indicates that investors are willing to pay a premium relative to the current asset base. There is no fair ratio available, so there is limited guidance on what level this multiple could trend toward if expectations change.

Result: Price-to-book of 9.5x (OVERVALUED)

However, the story can change quickly if key trials underperform or if market sentiment shifts away from higher risk, loss making biotechs like Tango.

Next Steps

This setup has left investors split between concern and optimism, so it makes sense to review the data quickly and decide where you stand using the 1 key reward and 3 important warning signs.

Looking for more investment ideas?

If Tango has caught your attention, do not stop there. Broadening your watchlist now can help you spot opportunities before the crowd notices them.

• Target quality at a discount by checking stocks that screen well for cash flows and balance sheets using the 48 high quality undervalued stocks.
• Reduce potential portfolio shocks by focusing on companies that score well for resilience through the 70 resilient stocks with low risk scores.
• Get ahead of the market by tracking underfollowed companies with strong fundamentals using the screener containing 25 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.